Complementary Actions of Dopamine D2 Receptor Agonist and Anti-Vegf Therapy on Tumoral Vessel Normalization in a Transgenic Mouse Model

International Journal of Cancer - United States
doi 10.1002/ijc.30628
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Effects of 2-Bromoterguride, a Dopamine D2 Receptor Partial Agonist, on Cognitive Dysfunction and Social Aversion in Rats

Psychopharmacology
Pharmacology
2017English

Exercise Elevates Dopamine D2 Receptor in a Mouse Model of Parkinson's Disease: In Vivo Imaging With [18F]fallypride

Movement Disorders
Neurology
2010English

Analysis of the Actions of the Novel Dopamine Receptor-Directed Compounds (S)-Osu6162 and ACR16 at the D2 Dopamine Receptor

British Journal of Pharmacology
Pharmacology
2010English

Anti-Vegf Therapy in Breast and Lung Mouse Models of Cancers

Journal of Biomedicine and Biotechnology
2011English

D2 Dopamine Receptor Subtype-Mediated Hyperactivity and Amphetamine Responses in a Model of ADHD

Neurobiology of Disease
Neurology
2010English

Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

The Effects of Clozapine on Behavioural Responses to the Selective ‘D1-Like’ Dopamine Receptor Agonist, a 68930, and to the Selective ‘D2-Like’ Agonist, RU 24213

British Journal of Pharmacology
Pharmacology
1994English

D1 and D2 Dopamine Receptor mRNA in Rat Brain.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1991English

Expression of Fos-Related Antigens in the Nucleus Accumbens During Opiate Withdrawal and Their Attenuation by a D2 Dopamine Receptor Agonist

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy